Antithrombotic Drugs World Industry 2014-2024

©noticeThis material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision-gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur-chase and single copy is for personal use only.

Antithrombotic Drugs: World Industry and Market Prospects

2014-2024

www.visiongain.com

Contents

1. Executive Summary

1.1 What This Report Covers

1.2 Antithrombotic Drugs: World Industry and Market Prospects 2014-2024 Overview

1.3 Chapter Outlines

1.4 Research and Analysis Methods

1.5 Glossary of Terms in this Report

2.1 Understanding Haemostasis and Coagulation

2.2 What is Thrombosis

2.3 Complications of Thrombosis

2.3.1 Pulmonary Embolism: A Thrombus Blocking Blood Supply to the Lungs

2.3.2 Stroke Results From Blockage of Blood Flow to the Brain

2.3.3 Acute Coronary Syndrome (ACS): Blockage of Blood Supply to the Heart

2.4 Antithrombotic Drug Treatment

3.1 The World Antithrombotic Drug Market in 2012 and 2013

3.2 The World Antithrombotic Drug Market: An Overarching Revenue Forecast 2014-2024

3.3 Driving and Restraining Forces Affecting the Antithrombotic Drugs Market

3.3.1 An Increasing Patient Population Drives Market Growth

3.3.2 Intense Competition from Generics Threatens to Restrain the Market

3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue and Market Share

Predictions, 2018 and 2024

1. Executive Summary

2. Blood Clotting: Mechanisms, Disorders and Current Treatments

3. Antithrombotic Drugs: World Market 2014-2024

www.visiongain.com

Contents

3.5 The Future of the World Market for Antithrombotic Drugs by Therapeutic Class: Grouped

Revenue Forecasts, 2014-2024

3.6 Antiplatelet Drugs Were the Leading Therapeutic Class in 2012

3.7 Anticoagulant Drugs: Leading the Market from 2013 Onwards

3.7.1 Heparins: The Leading Anticoagulants of 2013, But Will This Continue?

3.7.2 Direct Thrombin Inhibitors Achieved High Growth in 2013

3.7.3 Direct Factor Xa Inhibitors: A Novel Therapeutic Class With Great Potential

3.7.4 Vitamin K Antagonists Have Led the Anticoagulant Drug Market for 60 Years

3.8 Fibrinolytics Will Continue to be a Staple of the Antithrombotic Drug Market

4.1 Which Were the Leading National Markets for Sales of Antithrombotic Drugs in 2012 and

2013?

4.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues and

Market Shares, 2018 and 2024

4.3 Which National Markets Will Grow Fastest to 2024?

4.4 The US: Dominating the Antithrombotic Drug Market from 2014-2024

4.5 The EU5: Are the Guidelines for Approval of Biosimilar LMWHs Set to Change?

4.5.1 Germany Leads the EU5

4.5.2 France: Healthcare System Reform Will Inhibit Sales Growth?

4.5.3 UK: What Does the Introduction of a Value-Based Pricing System Mean for the Market?

4.5.4 Italy’s Healthcare System – Advantages Conducive to Pharma Business

4.5.5 Spain: Reductions in Government Healthcare Spending Will Restrict Growth

4.6 Japan: The Aging Population Will Stimulate Demand for Antithrombotic Drugs from 2014-

2024

4. Leading National Markets 2014-2024

www.visiongain.com

Contents

4.7 The Chinese Antithrombotic Drug Market Will Capture Market Share

4.8 The Brazilian Antithrombotic Drug Market 2014-2024: Strong Growth as Universal

Healthcare Coverage is Expanded

4.9 The Indian Antithrombotic Drug Market is Hindered by Limited Government Healthcare

Spending

4.10 The Russian Antithrombotic Drug Market: Poor Healthcare Funding Will Prevent Expansive

Growth

5.1 Plavix and Lovenox Remain the Market Leaders in 2012 and 2013, Despite Generic

Competition

5.2 The Leading Antithrombotic Drugs: Comparison of Revenue and Market Share, 2018 and

2024

5.3 Which Medicines Will Achieve the Highest Rates of Growth to 2024?

5.4 Plavix Faces Competition From 14 Generic Competitors, So What Does the Future Hold?

5.4.1 Branded Competition for Plavix?

5.5 Lovenox: Biosimilar Competition in the EU is Expected

5.6 Pradaxa Was the Leading Novel Oral Anticoagulant in 2013, but the Race is Heating Up

5.7 Xarelto Leads the Direct Factor Xa Inhibitor Market

5.8 Activase Leads the Fibrinolytics Market, With Little Competition

5.9 Effient Competes with Brilinta as well as Generic Competition for Plavix

5.10 Aspirin Cardio: The Most Lucrative Version of Acetylsalicylic Acid

5.11 Angiomax is Losing Share of the Direct Thrombin Inhibitors Market to Pradaxa

5.12 Pletal Faces Generic Competition and Restrictions on Use in Europe

5.13 Aggrenox to Face Generic Competition Earlier Than Expected in the US

5. The Leading Products in the Market, 2014-2024

www.visiongain.com

Contents

5.14 Sandoz’s Enoxaparin Sodium: Revenue Forecast 2014-2024

5.15 Fragmin Faces Rivalry from Generic Competition to Lovenox

5.16 Arixtra: Aspen Has Acquired Worldwide Rights from GSK

5.17 Brilinta: Facing Investigation

5.18 Eliquis: Will Late Entry to the Market Affect Uptake?

6.1 The R&D Pipeline for Antithrombotic Drugs: An Overview

6.2 The Antiplatelet Drug R&D Pipeline in 2014

6.2.1 FDA Advisory Committee Has Voted in Favour of Merck’s Vorapaxar

6.2.2 Pozen is Seeking a Strategic Partner for its Antiplatelet Drug, PA32540

6.2.3 The Medicine Company’s Cangrelor Awaits Approval

6.3 The R&D Pipeline for Anticoagulants, 2014

6.3.1 Heparins: Little R&D Activity in 2014

6.3.1.1 Will Development of Momenta’s Adomiparin Continue?

6.3.1.2 The Discontinuation of Semuloparin

6.3.2 The Vitamin K Antagonist Pipeline: One Product in Development in 2014

6.3.3 Many Development Direct Thrombin Inhibitors Have Been Discontinued

6.3.4 The Direct Factor Xa Inhibitor Pipeline: Only Two Compounds Remain

6.3.4.1 Daiichi Sankyo’s Lixiani (edoxaban) Awaits Approval in the US and the EU

6.3.5 Portola Pharmaceuticals’ Betrixaban

6.3.6 Sanofi Has Discontinued Development of Otamixaban

6.4 The Fibrinolytics R&D Pipeline, 2014

6.4.1 Lundbeck’s Desmoteplase

6. The Antithrombotic Drug Development Pipeline 2014-2024

www.visiongain.com

Contents

6.4.2 Bharat Biotech and ThromboGenics’ THR-100

6.5 The R&D Pipeline for Other Antithrombotic Drugs, 2013

6.5.1 Asahi Kasei Pharma America’s ART 123

6.5.2 Regado Biosciences is Developing an Anticoagulation System with an Antidote

6.5.3 Isis Pharmaceuticals’ ISIS-FXI Rx

7.1 Leading Antithrombotic Drug Manufacturers in 2013

7.2 Sanofi Leads the Market, but is its Position Under Threat?

7.3 Bristol-Myers Squibb Had a Dramatic Loss of Market Share in 2013

7.4 Boehringer Ingelheim is Captures Market Share

7.5 Bayer Markets Two Antithrombotic Drugs

7.6 Johnson & Johnson Can Achieve Success With a Limited Product Portfolio

7.7 Genentech Will Retain Market Share

7.8 The Medicines Company’s Position Will be Bolstered by the Launch of its New Drug

7.9 Otsuka: A Limited Antithrombotic Drug Portfolio

7.10 Eli Lilly: Market Position is Dependent on Success of Effient

7.11 Sandoz: A Gradually Declining Share of the Market

8.1 The Strengths and Weaknesses of the Antithrombotic Drug Market in 2014

8.1.1 Thrombotic Disease: Management Rather Than Cure

8.1.2 The Lack of Antidotes for the Novel Oral Anticoagulants Restricts the Market

7. Leading Companies in the Antithrombotic Drug Market

8. Qualitative Analysis of the Antithrombotic Drug Market, 2014-

2024

www.visiongain.com

Contents

8.2 The Opportunities and Threats Facing the Market 2014-2024

8.2.1 Rising Disease Prevalence Creates Opportunities in the Market

8.2.2 Further Development of Existing Drugs

8.2.3 High Demand for Antidotes to the Novel Oral Anticoagulants

8.2.4 The Threat of Generic Competition

8.2.5 High Level of Competition is a Threat to New Entrants - What Can Developers Do?

8.2.6 High Risk of Investment in New Drug Development

8.2.7 Healthcare Budget Pressures Threaten Drug Launches and Prices in Europe

8.3 The Social, Technological, Economic and Political Factors Influencing the Antithrombotic

Drug Market 2014-2024

8.3.1 Social Factors: An Expanding Patient Population and Increasing Awareness

8.3.2 Technological Advances Encourage the Development of Improved Treatment Options

8.3.3 Economic Factors

8.3.3.1 Cost Cutting in the EU and the US

8.3.3.2 Free Trade Within the EU Presents Challenges

8.3.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Antithrombotic

Drugs?

9.1 Interview with Dr Marcelo A. Lima, Research Fellow and Professor of Molecular Biology,

Department of Biochemistry, Universidade Federal de São Paulo, Brazil

9.1.1 Recent Research on a Novel Heparin-Like Compound Derived From Shrimp

9.1.2 Heparin vs. Novel Oral Anticoagulants

9.1.3 Unmet Needs in Brazil and Worldwide

9. Research Interviews

www.visiongain.com

Contents

9.1.4 Trends in the Antithrombotic Drug Market

9.2 Interview with Dr Frank Peacock, Professor, Associate Chair and Research Director, Baylor

College of Medicine, Houston, Texas

9.2.1 Warfarin vs. Novel Oral Anticoagulants

9.2.2 The Unmet Needs of the Market

9.2.3 The Antithrombotic R&D Pipeline

9.2.4 Key Market Drivers and Restraints

9.3 Interview with Dr Walter Ageno, Associate Professor of Medicine, Department of Clinical

and Experimental Medicine, University of Insubria, Italy

9.3.1 Unmet Needs

9.3.2 Future Focus of Antithrombotic Therapy

9.3.3 The Antithrombotic R&D Pipeline

9.3.4 Key Market Drivers and Restraints

9.3.5 Opportunities in the Market

9.4 Interview with Dr Jonathan L. Halperin, Professor of Medicine, Director of Clinical Cardiology

Services, Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center,

New York

9.4.1 Unmet Needs

9.4.2 New Findings

9.4.3 Warfarin Replacement

9.4.4 Areas Demanding Attention

9.4.5 Key Market Restraints

10.1 The World Market for Antithrombotic Drugs 2014-2024

10. Conclusions from Our Study

www.visiongain.com

Contents

10.1.1 The Decline of Antiplatelet Drugs and the Rise of the Anticoagulants

10.2 The Leading National Markets 2014-2024

10.3 Trends in the Industry

10.3.1 The Market Will Recover From Plavix Decline

10.3.2 The Demand for Antithrombotic Drugs is Increasing Worldwide

10.3.3 Many Drugs Will Face Generic Competition Over the Coming 10 Years

10.3.4 High Barriers to Market Entry and a Limited Pipeline – The Implications

www.visiongain.com

Contents

Table 1.1 Currency Exchange Rates, 2012 and 2013

Table 2.1 An Overview of Antithrombotic Drugs by Therapeutic Class, 2014

Table 3.1 The Antithrombotic Drug Market by Therapeutic Class: Revenues ($m) and Market

Shares (%), 2012 and 2013

Table 3.2 The Global Market for Antithrombotic Drugs: Revenue Forecast ($m), 2013-2024

Table 3.3 The Antithrombotic Drug Market by Therapeutic Class: Comparison of Revenues ($m)

and Market Shares (%), 2018 and 2024

Table 3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue ($m) and Market

Share (%) Forecasts, 2013-2024

Table 3.5 Antiplatelet Drugs: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 3.6 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2013-2024

Table 3.7 Heparins: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 3.8 Direct Thrombin Inhibitors: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 3.9 Direct Factor Xa Inhibitors: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 3.10 The Warfarin Market: Companies and Year of Introduction

Table 3.11 Vitamin K Antagonists: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 3.12 Fibrinolytics: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 4.1 The Leading National Markets for Antithrombotic Drugs: Revenues ($m) and Market

Shares (%), 2012 and 2013

Table 4.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues

($m) and Market Shares (%), 2018 and 2024

Table 4.3 The Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m),

2013-2024

List of Tables

www.visiongain.com

Contents

Table 4.4 The US Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast,

2013-2024

Table 4.5 The EU5 Market for Antithrombotic Drugs: Revenue Forecasts ($m), 2013-2024

Table 4.6 The German Antithrombotic Drug Market: Revenue ($m) and Market Share (%)

Forecast, 2013-2024

Table 4.7 The French Antithrombotic Drug Market: Revenue ($m) and Market Share (%)

Forecast, 2013-2024

Table 4.8 The UK Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast,

2013-2024

Table 4.9 The Italian Antithrombotic Drug Market: Revenue ($m) and Market Share (%)

Forecast, 2013-2024

Table 4.10 The Spanish Antithrombotic Drug Market: Revenue ($m) and Market Share (%)

Forecast, 2013-2024

Table 4.11 The Japanese Antithrombotic Drug Market: Revenue ($m) and Market Share (%)

Forecast, 2013-2024

Table 4.12 The Chinese Antithrombotic Drug Market: Revenue ($m) and Market Share (%)

Forecast, 2013-2024

Table 4.13 The Brazilian Antithrombotic Drug Market: Revenue ($m) and Market Share (%)

Forecast, 2013-2024

Table 4.14 The Indian Antithrombotic Drug Market: Revenue ($m) and Market Share (%)

Forecast, 2013-2024

Table 4.15 The Russian Antithrombotic Drug Market: Revenue ($m) and Market Share (%)

Forecast, 2013-2024

Table 5.1 The Leading Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2012 and

2013

Table 5.2 The Leading Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares

(%), 2018 and 2024

www.visiongain.com

Contents

Table 5.3 The Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2013-2024

Table 5.4 Plavix: Key Facts, 2014

Table 5.5 Plavix: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 5.6 Lovenox: Key Facts, 2014

Table 5.7 Lovenox: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 5.8 Pradaxa: Key Facts, 2014

Table 5.9 Pradaxa: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 5.10 Xarelto: Key Facts, 2014

Table 5.11 Xarelto: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 5.12 Activase: Key Facts, 2014

Table 5.13 Activase: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 5.14 Effient: Key Facts, 2014

Table 5.15 Effient: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 5.16 Aspirin Cardio: Key Facts, 2014

Table 5.17 Aspirin Cardio: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 5.18 Angiomax: Key Facts, 2014

Table 5.19 Angiomax: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 5.20 Pletal: Key Facts, 2014

Table 5.21 Pletal: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 5.22 Aggrenox: Key Facts, 2014

Table 5.23 Aggrenox: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 5.24 Sandoz’s Enoxaparin Sodium: Key Facts, 2014

Table 5.25 Sandoz’s Enoxaparin Sodium: Revenue ($m) and Market Share (%) Forecast, 2013-

2024

www.visiongain.com

Contents

Table 5.26 Fragmin: Key Facts, 2014

Table 5.27 Fragmin: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 5.28 Arixtra: Key Facts, 2014

Table 5.29 Arixtra: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 5.30 Brilinta: Key Facts, 2014

Table 5.31 Brilinta: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 5.32 Eliquis: Key Facts, 2014

Table 5.33 Eliquis: Revenue ($m) and Market Share (%) Forecast, 2013-2024

Table 6.1 The Antiplatelet Drug R&D Pipeline, 2014

Table 6.2 The Heparins Pipeline, 2014

Table 6.3 The Vitamin K Antagonist Pipeline, 2014

Table 6.4 The Direct Thrombin Inhibitors Pipeline, 2014

Table 6.5 The Direct Factor Xa Inhibitor Pipeline, 2014

Table 6.6 The Fibrinolytics R&D Pipeline, 2014

Table 6.7 Other Antithrombotic Drugs in the Pipeline, 2014

Table 7.1 The Top 10 Companies: Revenues ($m) and Market Shares (%), 2012 and 2013

Table 7.2 Sanofi: Antithrombotic Drug Portfolio, 2014

Table 7.3 Bristol-Myers Squibb: Antithrombotic Drug Portfolio, 2014

Table 7.4 Boehringer Ingelheim: Antithrombotic Drug Portfolio, 2014

Table 7.5 Bayer: Antithrombotic Drug Portfolio, 2014

Table 7.6 Johnson & Johnson: Antithrombotic Drug Portfolio, 2014

Table 7.7 Genentech: Antithrombotic Drug Portfolio, 2014

Table 7.8 The Medicines Company: Antithrombotic Drug Portfolio, 2014

Table 7.9 Otsuka: Antithrombotic Drug Portfolio, 2014

www.visiongain.com

Contents

Table 7.10 Eli Lilly: Antithrombotic Drug Portfolio, 2014

Table 7.11 Sandoz: Antithrombotic Drug Portfolio, 2014

Table 8.1 Strengths and Weaknesses of the Antithrombotic Drug Market, 2014

Table 8.2 Opportunities and Threats Facing the Antithrombotic Drug Market, 2014-2024

Table 8.3 Social, Technological, Economic and Political Factors Influencing the Antithrombotic

Drug Market (STEP Analysis), 2014-2024

www.visiongain.com

Contents

Figure 2.1 Diagram Depicting the Coagulation Cascade, 2013

Figure 3.1 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2012


Figure 3.3 The Global Market for Antithrombotic Drugs: Revenue Forecast ($m), 2013-2024

Figure 3.4 The Antithrombotic Drug Market: Drivers and Restraints, 2014-2024



Figure 3.7 The Antithrombotic Drug Market by Therapeutic Class: Revenue Forecasts ($m),

2013-2024

Figure 3.8 Antiplatelet Drugs: Revenue Forecast ($m), 2013-2024

Figure 3.9 The Antiplatelet Drug Market: Drivers and Restraints, 2014-2024

Figure 3.10 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2013-2024

Figure 3.11 Heparins: Revenue Forecast ($m), 2013-2024

Figure 3.12 The Heparins Market: Drivers and Restraints, 2014-2024

Figure 3.13 Direct Thrombin Inhibitors: Revenue Forecast ($m), 2013-2024

Figure 3.14 The Direct Thrombin Inhibitors Market: Drivers and Restraints, 2014-2024

Figure 3.15 Direct Factor Xa Inhibitors: Revenue Forecast ($m), 2013-2024

Figure 3.16 Direct Factor Xa Inhibitors Market: Drivers and Restraints, 2014-2024

Figure 3.17 Vitamin K Antagonists: Revenue Forecast ($m), 2013-2024

Figure 3.18 The Vitamin K Antagonist Market: Drivers and Restraints, 2014-2024

Figure 3.19 Fibrinolytics: Revenue Forecast ($m), 2013-2024

Figure 3.20 The Fibrinolytics Market: Drivers and Restraints, 2014-2024

List of Figures

www.visiongain.com

Contents

Figure 4.1 The Antithrombotic Drug Market by Country: Market Shares (%), 2012




Figure 4.5 Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2013-

2024

Figure 4.6 The US Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024

Figure 4.7 The US Antithrombotic Drug Market: Drivers and Restraints, 2014-2024

Figure 4.8 EU5 Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2013-2024

Figure 4.9 EU5 Antithrombotic Drug Market: Drivers and Restraints, 2014-2024

Figure 4.10 The German Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024

Figure 4.11 The French Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024

Figure 4.12 The UK Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024

Figure 4.13 The Italian Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024

Figure 4.14 The Spanish Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024

Figure 4.15 The Japanese Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024

Figure 4.16 The Japanese Antithrombotic Drug Market: Drivers and Restraints, 2014-2024

Figure 4.17 The Chinese Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024

Figure 4.18 The Chinese Antithrombotic Drug Market: Drivers and Restraints, 2014-2024

Figure 4.19 The Brazilian Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024

Figure 4.20 The Brazilian Antithrombotic Drug Market: Drivers and Restraints, 2014-2024

Figure 4.21 The Indian Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024

Figure 4.22 The Indian Antithrombotic Drug Market: Drivers and Restraints, 2014-2024

Figure 4.23 The Russian Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024

www.visiongain.com

Contents

Figure 4.24 The Russian Antithrombotic Drug Market: Drivers and Restraints, 2014-2024

Figure 5.1 The Leading Antithrombotic Drugs: Market Shares (%), 2012




Figure 5.5 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2013-2024

Figure 5.6 Plavix: Revenue Forecast ($m), 2013-2024

Figure 5.7 Lovenox: Revenue Forecast ($m), 2013-2024

Figure 5.8 Pradaxa: Revenue Forecast ($m), 2013-2024

Figure 5.9 Xarelto: Revenue Forecast ($m), 2013-2024

Figure 5.10 Activase: Revenue Forecast ($m), 2013-2024

Figure 5.11 Effient: Revenue Forecast ($m), 2013-2024

Figure 5.12 Aspirin Cardio: Revenue ($m) Forecast, 2013-2024

Figure 5.13 Angiomax: Revenue Forecast ($m), 2013-2024

Figure 5.14 Pletal: Revenue Forecast ($m), 2013-2024

Figure 5.15 Aggrenox: Revenue Forecast ($m), 2013-2024

Figure 5.16 Sandoz’s Enoxaparin Sodium: Revenue Forecast ($m), 2013-2024

Figure 5.17 Fragmin: Revenue Forecast ($m), 2013-2024

Figure 5.18 Arixtra: Revenue Forecast ($m), 2013-2024

Figure 5.19 Brilinta: Revenue Forecast ($m), 2013-2024

Figure 5.20 Eliquis: Revenue Forecast ($m), 2013-2024

Figure 6.1 An Overview of the R&D Pipeline for Antithrombotic Drugs, 2014

Figure 7.1 The Top 10 Leading Companies: Market Shares (%), 2012

Figure 7.2 The Top 10 Leading Companies: Market Shares (%), 2013

www.visiongain.com

Contents

Figure 10.1 The Global Antithrombotic Drug Market by Therapeutic Class: Comparison of

Revenues ($m), 2013-2024

Figure 10.2 The National Markets for Antithrombotic Drugs: Comparison of Revenues ($m),

2012, 2018 and 2024

www.visiongain.com

Contents

Companies Listed

Abbott Laboratories

Ablynx

Aché

AdvanceCor

Alchemia

Amneal Pharms

Amphastar Pharmaceuticals

App Pharmaceuticals

ARCA Biopharma

Armetheon

ARYx Therapeutics

Asahi Kasei Pharma America

Aspen

Astellas Pharma

AstraZeneca

Barr Laboratories

Bayer

Baylor College of Medicine, Houston, Texas

Bharat Biotech

BioVascular

Boehringer Ingelheim

Bristol-Myers Squibb

Canyon Pharmaceuticals

Companies and Other Organisations Mentioned

www.visiongain.com

Contents

Committee on Medicinal Products for Human Use (CHMP)

CSL Behring

Daiichi Sankyo

Dexa Medica Group

Diakron Pharmaceuticals

Dr. Reddy’s Laboratories

DuPont Merck

Eisai

Eli Lilly

EMS

Endo Laboratories

ESP Pharma

Eurofarma

European Medicines Agency (EMA)

Food and Drug Administration (US FDA)

Fournier Pharma

Gate Pharmaceuticals

Genentech

German Institute for Quality and Efficiency in Health Care (IQWiG)

GlaxoSmithKline (GSK)

Grifols Therapeutics

Hoechst Marion Roussell

Hospira

Hypermarcas

www.visiongain.com

Contents

Indonesia University

Invagen Pharms

IPCA Labs

Isis Pharmaceuticals

Johns Hopkins Medicine

Johnson & Johnson (J&J)

Kowa

Kyowa Hakko

Lee’s Pharmaceutical

LG Life Sciences

LIMES Institute

Lundbeck

Merck & Co.

Mitsubishi

Mitsubishi Tanabe Pharma

Momenta Pharmaceuticals

Mylan Pharmaceuticals

National Health Service (NHS)

National Institute for Health and Care Excellence (NICE)

Novartis

Nuvelo

Organon

Otsuka Pharmaceutical Company

Pfizer

www.visiongain.com

Contents

Pharmaceutical and Medical Devices Agency (PMDA)

Pharmacia

PLIVA

PLx Pharma

Portola Pharmaceuticals

Pozen

Regado Biosciences

Roche

Sandoz

Sanofi

Sun Pharmaceuticals

Takeda

Taro

Teva Pharmaceuticals

The Medicines Company

ThromboGenics

Tianjin Medical

Tufts Medical Center

Unified Health System (SUS)

Universidade Federal de São Paulo

University General Hospital

University of Insubria (Italy)

Upjohn AB

US Department of Justice

www.visiongain.com

Contents

USL Pharma

Virginia Commonwealth University

World Health Organization (WHO)

Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York

Zydus Cadila

www.visiongain.com Page 84

Antithrombotic Drugs: World Industry and Market Prospects 2014-2024

Between 2012 and 2018, the Chinese antithrombotic drug market will expand at a CAGR of 5.87%.

From 2021 onwards, the market will see declining revenue as a result of generic versions of the

market leading drugs flooding the market. Between 2018 and 2024, the Chinese market will

contract at a CAGR of -1.78%. This contraction will be less than that of the developed nations,

since the Chinese market is not dominated by branded products. In 2024, sales of antithrombotic

drugs in China will generate $1,374m, accounting for 7.9% of the global market.

Figure 4.18 The Chinese Antithrombotic Drug Market: Drivers and Restraints, 2014-2024

4.8 The Brazilian Antithrombotic Drug Market 2014-2024: Strong

Growth as Universal Healthcare Coverage is Expanded

In 2013, the Brazilian antithrombotic drug market generated $523m, accounting for 3% of the

global market. In that year, the market saw 11% growth, driven by the increasing up take of Plavix

as well as other antithrombotic drugs. Cardiovascular diseases are the largest cause of death in

Brazil. As such, the demand for antithrombotic drugs is high. Generic drugs have a strong

presence in Brazil, accounting for 17% of that pharmaceutical market in 2012.

The Brazilian government’s policies have helped to build the domestic generics industry, with

EMS, Hypermarcas, Aché and Eurofarma prominent companies. This domestic industry is

improving access to healthcare for the Brazilian population, by producing affordable drugs. That is

Source: visiongain 2014

• Increasing patient population.

• Severity of indicated conditions.

• Expansion of government healthcare coverage.

Drivers Restraints

• IP protection remains a concern.

• Market is dominated by low-cost generics.

www.visiongain.com Page 85

Antithrombotic Drugs: World Industry and Market Prospects 2014-2024

a large population, and as access improves, demand for pharmaceuticals is increasing; the generic

drugs sector is the fastest growing of the Brazilian pharmaceutical market.

At present, a significant proportion of the population remain under-served by the public health

service. However, the government strives to widen access to health services and medicines,

fuelling growth in the market over the forecast period. At the same time, affluent people are

improving their cover with private healthcare. This is resulting in an increasing demand for branded

drugs. To help meet this demand, increasingly the government establishes technology-transfer

deals to bring the production of patented drugs into the country. This will also fuel growth in the

antithrombotic drug market. Multinational leaders in Brazil include Sanofi, Novartis, Roche and

Merck & Co. There is much interest from multinational pharma companies in trading with and in

Brazil.

Table 4.13 The Brazilian Antithrombotic Drug Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024Market Share (%) 2.60 3.00 3.07 3.12 3.17 3.20 3.25 3.30 3.35 3.40 3.45 3.50 3.60Revenue ($m) 471 523 550 576 605 630 663 683 702 688 674 653 626AGR (%) 11 5 5 5 4 5 3 3 -2 -2 -3 -4CAGR (%) 5.87 -0.95

Figure 4.19 The Brazilian Antithrombotic Drug Market: Revenue Forecast ($m), 2013-2024

0

100

200

300

400

500

600

700

800

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

Reve

nue

($m

)

Year

Source: visiongain 2014; CAGR values for year ranges 2012-2018 and 2018-2024

Source: visiongain 2014